Vyome Holdings HIND
Vyome Holdings Q2 FY25: revenue $50K; diluted EPS −$2.25
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-25-011594
Key figures from this report
These are the numbers Vyome Holdings reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$50KNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$2.6MAgainst −$1.6M in Q2 FY2410-Q income statement, on EDGAR
- Diluted EPS−$2.25Against −$5,129.96 in Q2 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$4.1M+292% from $1.1M in Q2 FY2410-Q balance sheet, on EDGAR
- Cash from operations−$4.5MAgainst −$1.4M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- AIM ImmunoTech AIM public float $6M, Jun 30, 2025
- Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
- PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025
- Natural Alternatives International NAII public float $6M, Dec 31, 2025
- LFTD Partners LIFD public float $6M, Jun 30, 2025
